C-LECTA
26.5.2021 10:19:08 CEST | Business Wire | Press release
c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, has submitted dossiers for two newly developed enzymes in the food sector. The evaluation by EFSA (European Food Safety Agency) and the EU Commission is based on the harmonized EU approval procedure for food improvement agents (food enzymes, food additives and food flavors). The enzyme dossiers submitted by c-LEcta for products in the target market of the food industry complement the company’s offering to its customers, who thus no longer have to worry separately about approvals for the use of the enzymes.
The two dossiers were submitted as part of an exclusive collaboration with an industry partner in the food sector for two food enzymes. Both enzymes are used to produce a natural sugar, for example, that can replace lactose, which has recently become unpopular with consumers, in industrially processed foods. With the help of the c-LEcta enzymes and the process developed by the cooperation partner, this sugar can be extracted from readily available sugar beets on a large scale.
“This is a typical case of enzymes making something entirely new and valuable possible. We are proud of this and, in cooperation with our partner, we are safeguarding this development result for the future. Thanks to our expertise in both new product development and regulatory matters, we can also provide our partners and customers with comprehensive support at this point,” explained Paula Pescador, responsible for enzyme dossiers at c-LEcta.
As part of the implementation of the FIAP (Food Improvement Agents Package), a new approval procedure was introduced for enzymes used in the production of food. This is intended to create a harmonized regulatory system for food enzymes throughout the European Union. Following evaluation by the European Food Safety Authority (EFSA), the EU Commission will draw up a positive list of enzymes approved in the EU for use in the food industry in the future. So-called enzyme dossiers have to be submitted for inclusion in this list, demonstrating the safety and technical necessity of the enzymes. The first publication of the new list is planned for 2023. From that date on, food manufacturers will only be allowed to use the enzymes listed. To provide customers with planning security, c-LEcta is therefore ensuring the necessary submission of enzyme dossiers so that the enzymes can already be included in the list when it is first published.
“The EU enzyme approval is of course a new process that everyone in the industry has to get used to. However, for us at c-LEcta, this is not a problem thanks to our in-house expertise and flexibility. On the other hand, the European positive list also offers us a simplification for the approval of new products for the food industry. Of course, we will continue to handle this in such a way that we submit these dossiers for all our products for the food industry. For us, this is a natural part of the service we provide to our customers,” concluded Dr. Marc Struhalla, founder and CEO of c-LEcta.
About c-LEcta
c-LEcta is a world-leading biotechnology company with a focus on enzyme engineering and application in regulated markets like the food and pharma industries. The company is based in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry. The company currently employs more than 100 people.
c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005470/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna to Power Apple Upgrade, a New Hardware Leasing Program Offered by Apple28.7.2026 14:15:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, today announced it would be the leasing provider behind the Apple Upgrade program, a new hardware leasing option available from Apple in the United States. Lease Apple hardware for low monthly payments Provided by Klarna, Apple Upgrade offers customers a new way to pay for eligible iPhone, Mac, iPad and Apple Watch. Customers can select from 12- and 24-month leasing options for iPhone and Apple Watch, and 24- and 36-month leasing options for Mac and iPad. In addition, when customers first enroll in Apple Upgrade, they can trade in an existing device to further lower their monthly payments during their initial lease term. The freedom to upgrade, return, or buy When the lease ends, customers choose what suits them: upgrade to the latest model1, purchase their device, or return it. A seamless checkout, and easy to manage payments Apple and Klarna have built an easy and seamless checkout experience which shows customers exactl
Third-Party EPDs Confirm C-Crete Cement Cuts Embodied Carbon by up to 95% — and It’s Already Being Poured Commercially28.7.2026 14:05:00 CEST | Press release
Two independently verified Environmental Product Declarations confirm cradle-to-gate carbon as low as 43.1 kg CO2-eq per metric ton. C-Crete’s platform technology turns a wide range of local rocks and industrial by-products into clinker-free cementitious binder — already in commercial use and adaptable to cement standards worldwide. C-Crete Technologies has published two Environmental Product Declarations (EPDs) verifying that its cements cut embodied carbon by up to 95% versus conventional portland cement. C-Crete’s technology converts a broad range of natural rocks and industrial by-products into cementitious binders with no clinker and no kiln, so production is inherently decentralized — and it is already being poured in commercial concrete today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728132467/en/ Representative C-Crete's project portfolio. More than 4000 tons of C-Crete's ultra-low carbon concrete have been
ExaGrid Releases Version 8.128.7.2026 14:00:00 CEST | Press release
Latest update includes support of Cohesity DataProtect, share quotas for MSPs, and NFS encryption over the wire ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most comprehensive security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced the release of ExaGrid software version 8.1. The latest version includes: Support for Cohesity DataProtect Uses S3 protocol. Supports Cohesity Cloud Archive Direct. ExaGrid further deduplicates Cohesity deduplicated data, cutting the storage footprint in half. ExaGrid works with Cohesity NetBackup for mixed NetBackup and DataProtect environments. NFS encrypted over the wire Available for backup apps that support NFS encryption over the wire. ExaGrid already supports encryption over the wire with other protocols such as the Veeam Data Mover, CIFS, and S3. Share Quota ExaGrid already tracks how much data is going into each share. Now, a Managed Service Provider (MSP) can s
Omilia Appoints David Ogden as VP of Revenue Operations28.7.2026 14:00:00 CEST | Press release
Enterprise SaaS revenue operations leader joins Omilia to build the operational backbone for its next phase of global growth Omilia, a global leader in Self-Learning Agentic CX, today announced the appointment of Dave Ogden as Vice President of Revenue Operations. Ogden will be responsible for scaling Omilia’s global revenue operations function spanning sales operations, forecasting, and commercial execution as the company accelerates growth across its key markets. In this role, Ogden will design and operate the revenue infrastructure that connects sales, marketing, and customer success, including forecasting, pipeline management, and deal desk operations. He joins as Omilia expands its direct and partner-led go-to-market across the US, Europe, Latin America and Australia, and will play a central role in ensuring that growth scales in a disciplined, data-driven way. Ogden brings more than 15 years of enterprise SaaS revenue and commercial operations experience. He spent nine years at F
Nine in 10 LPs More Likely to Commit to Funds Using Leverage When Disclosure is Clear28.7.2026 14:00:00 CEST | Press release
90% of LPs say adequate disclosure around fund-level leverage and liquidity tools would increase their likelihood to commit or re-upGPs use 2.4 liquidity tools on average as fund-level financing becomes embedded in private capital63% of GPs cite facility-data integration with accounting and investor reporting as a major operational challenge Fund-level leverage and liquidity tools have moved from specialist financing techniques to mainstream private capital infrastructure, according to new research from CSC, the leading provider of global business administration and compliance solutions. The findings show that limited partners (LPs) are increasingly open to the use of these tools when disclosure is clear, but general partners (GPs) face growing pressure to prove that the operating model behind them is controlled, transparent, and investor-ready. CSC¹ surveyed 300 GPs and 200 LPs across North America, Europe, the U.K., and Asia Pacific. The report, Future Private Capital CFO 2026: How C
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
